Study Number:

Study Gender:

PWG Approval Date:

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane CAS Number: 18107-18-1 Date Report Requested: 10/22/2020 Time Report Requested: 09:08:35 Lab: Battelle with CRL

C11049-01

Male

See web page for date of PWG Approval

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 1 Day Exposure							
		Treatment Groups (ppm)					
	0	10	25 ppm Hexanes				
Disposition Summary							
Animals Initially In Study	8	8	8				
Early Deaths							
Survivors							
Scheduled sacrifice, terminal (SD 1)	8	8	8				
Animals Examined Microscopically	8	8	8				
ALIMENTARY SYSTEM							
LIVER	(8)	(8)	(8)				
HEMATOPOIETIC CELL PROLIFERATION		1 (13%)					
PHARYNX	(8)	(8)	(8)				
HYPERPLASIA; SQUAMOUS		1 (13%)					
CARDIOVASCULAR SYSTEM							
AORTA	(8)	(8)	(8)				
HEART	(8)	(8)	(8)				
ENDOCRINE SYSTEM							
No Tissues/Organs Examined							
GENERAL BODY SYSTEM							
No Tissues/Organs Examined							
GENITAL SYSTEM							
No Tissues/Organs Examined		· · ·					
HEMATOLYMPHOID SYSTEM							
No Tissues/Organs Examined							
No Tissues/Organs Examined							
MUSCULOSKELETAL SYSTEM							
No Tissues/Organs Examined							

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 1 Day Exposure						
		Treatment Groups (ppm)				
	0	10	25 ppm Hexanes			
NERVOUS SYSTEM						
BRAIN	(8)	(8)	(8)			
NERVE, SCIATIC	(8)	(8)	(8)			
NERVE, TIBIAL	(8)	(8)	(8)			
TRIGEMINAL GANGLION	(8)	(8)	(8)			
RESPIRATORY SYSTEM						
LARYNX	(7)	(8)	(8)			
EPIGLOTTIS; INFLAMMATION		1 (13%)				
INFLAMMATION; CHRONIC-ACTIVE	1 (14%)					
EPIGLOTTIS; METAPLASIA; SQUAMOUS		1 (13%)				
LUNG	(8)	(8)	(8)			
ERYTHROPHAGOCYTOSIS		1 (13%)				
HEMORRHAGE; ACUTE	1 (13%)	1 (13%)				
INFILTRATION, CELLULAR; MIXED		1 (13%)				
NOSE	(8)	(8)	(8)			
TRACHEA	(8)	(8)	(8)			
EPITHELIUM; DEGENERATION		1 (13%)				
SPECIAL SENSES SYSTEM						
No Tissues/Organs Examined						
URINARY SYSTEM						
KIDNEY, LEFT	(8)	(8)	(8)			
INFILTRATE, CELLULAR; MIXED		1 (13%)	2 (25%)			
NEPHROPATHY	2 (25%)	3 (38%)	1 (13%)			

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 1 Day Recovery							
		Treatment Groups (ppm)					
	0	10	25 ppm Hexanes				
Disposition Summary							
Animals Initially In Study	8	8	8				
Early Deaths							
Survivors							
Scheduled sacrifice, terminal (SD 9)	8	8	8				
Animals Examined Microscopically	8	8	8				
ALIMENTARY SYSTEM							
LIVER	(8)	(8)	(8)				
CLEAR CELL FOCUS		1 (13%)					
HEMATOPOIETIC CELL PROLIFERATION			1 (13%)				
HEPATODIAPHRAGMATIC NODULE	1 (13%)						
PHARYNX	(8)	(8)	(8)				
CARDIOVASCULAR SYSTEM							
AORTA	(8)	(8)	(8)				
HEART	(8)	(8)	(8)				
ENDOCRINE SYSTEM							
No Tissues/Organs Examined							
GENERAL BODY SYSTEM							
No Tissues/Organs Examined							
GENITAL SYSTEM							
No Tissues/Organs Examined							
HEMATOLYMPHOID SYSTEM							
No Tissues/Organs Examined							
INTEGUMENTARY SYSTEM							
No Tissues/Organs Examined							
MUSCULOSKELETAL SYSTEM							
No Tissues/Organs Examined							

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 1 Day Recovery							
		Treatment Groups (ppm)					
	0	10	25 ppm Hexanes				
NERVOUS SYSTEM							
BRAIN	(8)	(8)	(8)				
NERVE, SCIATIC	(8)	(8)	(8)				
NERVE, TIBIAL	(8)	(8)	(8)				
TRIGEMINAL GANGLION	(8)	(8)	(8)				
RESPIRATORY SYSTEM							
LARYNX	(8)	(8)	(8)				
LUNG	(8)	(8)	(8)				
HEMORRHAGE; ACUTE		1 (13%)					
PERIVASCULAR; INFILTRATION, CELLULAR; MIXED			2 (25%)				
NOSE	(8)	(8)	(8)				
GOBLET CELL; HYPERPLASIA		1 (13%)					
INFLAMMATION; LYMPHOHISTIOCYTIC			1 (13%)				
TRACHEA	(8)	(8)	(8)				
SPECIAL SENSES SYSTEM							
No Tissues/Organs Examined							
URINARY SYSTEM							
KIDNEY, LEFT	(8)	(8)	(8)				
NEPHROPATHY	7 (88%)	3 (38%)	3 (38%)				

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 5 Day Exposure							
	Treatment Groups (ppm)						
	0	0.3	1	3	10	25 ppm Hexane	
Disposition Summary Animals Initially In Study	8	8	8	8	8	8	
Early Deaths Survivors							
Scheduled sacrifice, terminal (SD 5) Animals Examined Microscopically	8 8	8	8 8	8 8	8 8	8 8	
ALIMENTARY SYSTEM							
LIVER HEMATOPOIETIC CELL PROLIFERATION	(8)	(0)	(0)	(0)	(8) 1 (13%)	(8) 1 (13%)	
PHARYNX	(8)	(0)	(0)	(0)	(8)	(8)	
CARDIOVASCULAR SYSTEM							
AORTA	(8)	(0)	(0)	(0)	(8)	(8)	
HEART	(8)	(0)	(0)	(0)	(8)	(8)	
ENDOCRINE SYSTEM No Tissues/Organs Examined							
GENERAL BODY SYSTEM No Tissues/Organs Examined							
GENITAL SYSTEM No Tissues/Organs Examined							
HEMATOLYMPHOID SYSTEM		·			·		
LYMPH NODE, MEDIASTINAL LYMPHOID TISSUE; HYPERPLASIA	(8)	(0)	(7) 2 (29%)	(8)	(8)	(8) 1 (13%)	
INFILTRATION, CELLULAR; HISTIOCYTE			2 (2070)	1 (13%)	8 (100%)	2 (25%)	
INTEGUMENTARY SYSTEM						_ (=0,0)	
No Tissues/Organs Examined							
MUSCULOSKELETAL SYSTEM							
No Tissues/Organs Examined							

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 5 Day Exposure							
	Treatment Groups (ppm)						
	0	0.3	1	3	10	25 ppm Hexanes	
NERVOUS SYSTEM							
BRAIN	(8)	(0)	(0)	(0)	(8)	(8)	
NERVE, SCIATIC	(8)	(0)	(0)	(0)	(8)	(8)	
NERVE, TIBIAL	(8)	(0)	(0)	(1)	(8)	(8)	
TRIGEMINAL GANGLION	(8)	(0)	(0)	(0)	(7)	(8)	
RESPIRATORY SYSTEM							
LARYNX	(8)	(0)	(0)	(0)	(8)	(8)	
EPITHELIAL CELL; HYPERPLASIA; SQUAMOUS		.,			2 (25%)		
EPIGLOTTIS; METAPLASIA; SQUAMOUS					2 (25%)		
LUNG	(8)	(0)	(8)	(8)	(8)	(8)	
EDEMA					7 (88%)		
INTERSTITIUM; FIBROSIS					8 (100%)		
HEMORRHAGE; ACUTE					8 (100%)		
ALVEOLAR EPITHELIUM; HYPERPLASIA				6 (75%)	8 (100%)		
BRONCHIOLE EPITHELIUM; HYPERPLASIA				7 (88%)	8 (100%)		
INFILTRATION, CELLULAR; HISTIOCYTE				7 (88%)			
INFLAMMATION; CHRONIC-ACTIVE				7 (88%)	8 (100%)		
INFLAMMATION; CHRONIC-ACTIVE, FOCAL			2 (25%)				
NOSE	(8)	(0)	(0)	(0)	(8)	(8)	
TRACHEA	(8)	(0)	(0)	(0)	(8)	(8)	
EPITHELIUM; DEGENERATION						1 (13%)	
SPECIAL SENSES SYSTEM							
No Tissues/Organs Examined							
URINARY SYSTEM							
KIDNEY, LEFT	(8)	(0)	(0)	(0)	(8)	(8)	
NEPHROPATHY	3 (38%)					2 (25%)	

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 5 Day Recovery							
	Treatment Groups (ppm)						
	0	0.3	1	3	10	25 ppm Hexanes	
Disposition Summary							
Animals Initially In Study	8	8	8	8	8	8	
Early Deaths							
Survivors							
Scheduled sacrifice, terminal (SD 9)	8	8	8	8	8	8	
Animals Examined Microscopically	8	8	8	8	8	8	
ALIMENTARY SYSTEM							
LIVER	(8)	(0)	(0)	(0)	(8)	(8)	
PHARYNX	(8)	(0)	(0)	(0)	(8)	(8)	
CARDIOVASCULAR SYSTEM							
AORTA	(8)	(0)	(0)	(0)	(8)	(8)	
HEART	(8)	(0)	(0)	(0)	(8)	(8)	
ENDOCRINE SYSTEM							
No Tissues/Organs Examined							
GENERAL BODY SYSTEM							
No Tissues/Organs Examined							
GENITAL SYSTEM							
No Tissues/Organs Examined							
HEMATOLYMPHOID SYSTEM							
LYMPH NODE, MEDIASTINAL	(8)	(0)	(8)	(8)	(8)	(8)	
LYMPHOID TISSUE; HYPERPLASIA	1 (13%)		2 (25%)	2 (25%)	2 (25%)	1 (13%)	
INFILTRATION, CELLULAR; HISTIOCYTE	1 (13%)			5 (63%)	8 (100%)		
INTEGUMENTARY SYSTEM							
No Tissues/Organs Examined							
MUSCULOSKELETAL SYSTEM							
No Tissues/Organs Examined							

PA03: Non-Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

	Male: 5 Day Recovery						
	Treatment Groups (ppm)						
	0	0.3	1	3	10	25 ppm Hexanes	
NERVOUS SYSTEM							
BRAIN	(8)	(0)	(0)	(0)	(8)	(8)	
NERVE, SCIATIC	(8)	(0)	(0)	(0)	(8)	(8)	
NERVE, TIBIAL	(8)	(0)	(0)	(0)	(8)	(8)	
TRIGEMINAL GANGLION	(8)	(0)	(0)	(0)	(7)	(8)	
RESPIRATORY SYSTEM							
LARYNX	(8)	(0)	(0)	(0)	(8)	(8)	
INFILTRATION, CELLULAR; MIXED						2 (25%)	
LUNG	(8)	(8)	(8)	(8)	(8)	(8)	
EDEMA					7 (88%)		
INTERSTITIUM; FIBROSIS					8 (100%)		
HEMORRHAGE; ACUTE		1 (13%)	1 (13%)	3 (38%)	8 (100%)		
ALVEOLAR EPITHELIUM; HYPERPLASIA			1 (13%)	2 (25%)	8 (100%)		
BRONCHIOLE EPITHELIUM; HYPERPLASIA					6 (75%)		
INFILTRATION, CELLULAR; HISTIOCYTE		1 (13%)	2 (25%)	8 (100%)			
INFLAMMATION; CHRONIC-ACTIVE			2 (25%)	8 (100%)	8 (100%)		
INFLAMMATION; CHRONIC-ACTIVE, FOCAL	1 (13%)	3 (38%)				1 (13%)	
NOSE	(8)	(0)	(0)	(0)	(8)	(8)	
INFILTRATION, CELLULAR; NEUTROPHIL					2 (25%)		
INFLAMMATION; CHRONIC						1 (13%)	
TRACHEA	(8)	(0)	(0)	(0)	(8)	(8)	
EPITHELIUM; DEGENERATION					1 (13%)		
SPECIAL SENSES SYSTEM							
No Tissues/Organs Examined							
URINARY SYSTEM							
KIDNEY, LEFT	(8)	(0)	(0)	(0)	(8)	(8)	
NEPHROPATHY	2 (25%)		. ,		6 (75%)	1 (13%)	

Date Report Requested: 10/22/2020 Time Report Requested: 09:08:35 Lab: Battelle with CRL

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD - Study Day

The 1 Day Exposure animals were exposed for one day and then sacrificed on study day 1 (first day of exposure was study day 0); the 1 Day Recovery animals were exposed for 1 day and then sacrificed on study day 9; the 5 Day Exposure animals were exposed for five days and then sacrificed on study day 5; the 5 Day Recovery animals were exposed for five days and then sacrificed on study day 5.

** END OF REPORT **